Contrasting Skye Bioscience (SKYE) and Its Rivals

Skye Bioscience (NASDAQ:SKYEGet Free Report) is one of 955 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Skye Bioscience to related businesses based on the strength of its institutional ownership, analyst recommendations, dividends, profitability, valuation, earnings and risk.


This table compares Skye Bioscience and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Skye Bioscience N/A N/A -438.15%
Skye Bioscience Competitors -2,643.56% -227.01% -28.96%

Institutional & Insider Ownership

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 0.7% of Skye Bioscience shares are held by insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Skye Bioscience and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Skye Bioscience 0 0 2 0 3.00
Skye Bioscience Competitors 6095 17833 42985 885 2.57

Skye Bioscience presently has a consensus target price of $22.50, suggesting a potential upside of 32.59%. As a group, “Pharmaceutical preparations” companies have a potential upside of 86.00%. Given Skye Bioscience’s competitors higher probable upside, analysts clearly believe Skye Bioscience has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Skye Bioscience and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Skye Bioscience N/A -$37.65 million -1.59
Skye Bioscience Competitors $1.66 billion $154.05 million -3.88

Skye Bioscience’s competitors have higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Skye Bioscience has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Skye Bioscience’s competitors have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.


Skye Bioscience competitors beat Skye Bioscience on 7 of the 13 factors compared.

Skye Bioscience Company Profile

(Get Free Report)

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with's FREE daily email newsletter.